<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854216</url>
  </required_header>
  <id_info>
    <org_study_id>SP0718</org_study_id>
    <nct_id>NCT01854216</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects</brief_title>
  <official_title>Parallel Group Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Repeated Dose Treatment With Rotigotine Continuous Delivery System (5 cm^2/2.25 mg, 10 cm^2/4.5 mg, 20 cm^2/9 mg) in Japanese and Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB BIOSCIENCES GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the repeated dose Pharmacokinetics (PK) of transdermally delivered Rotigotine
      in Japanese and Caucasian female and male healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of unconjugated Rotigotine in steady-state within one dosing interval (AUCtau,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of unconjugated Rotigotine in steady-state within one dosing interval normalized by Body Weight [AUCtau,ss,norm(BW)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of unconjugated Rotigotine in plasma at steady-state (Cmax,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by Body Weight [Cmax,ss,norm(BW)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by apparent dose [Cmax,ss,norm(appd)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by Body Weight and apparent dose [Cmax,ss,norm(BW,appd)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of total Rotigotine in steady-state within one dosing interval (AUCtau,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of total Rotigotine in steady-state within one dosing interval normalized by Body Weight [AUCtau,ss,norm(BW)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of total Rotigotine in plasma at steady-state (Cmax,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of total Rotigotine in plasma at steady-state normalized by Body Weight [Cmax,ss,norm(BW)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of total Rotigotine in plasma at steady-state normalized by apparent dose [Cmax,ss,norm(appd)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of total Rotigotine in plasma at steady-state normalized by Body Weight and apparent dose [Cmax,ss,norm(BW,appd)]</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of unconjugated Rotigotine in steady-state</measure>
    <time_frame>Blood sampling at 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (tmax) of unconjugated Rotigotine in steady-state (tmax,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance of unconjugated Rotigotine normalized by Body Weight (CL/f/BW)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of unconjugated Rotigotine normalized by Body Weight (Vz/f/BW)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of total Rotigotine in steady-state</measure>
    <time_frame>Blood sampling at 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (tmax) of total Rotigotine in steady-state (tmax,ss)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance of total Rotigotine normalized by Body Weight (CL/f/BW)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of total Rotigotine normalized by Body Weight (Vz/f/BW)</measure>
    <time_frame>Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rotigotine in Japanese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine in Caucasian subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine transdermal patch 1mg / 24 hours</intervention_name>
    <description>Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours</description>
    <arm_group_label>Rotigotine in Japanese subjects</arm_group_label>
    <arm_group_label>Rotigotine in Caucasian subjects</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine transdermal patch 2 mg / 24 hours</intervention_name>
    <description>Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours</description>
    <arm_group_label>Rotigotine in Japanese subjects</arm_group_label>
    <arm_group_label>Rotigotine in Caucasian subjects</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine transdermal patch 4 mg / 24 hours</intervention_name>
    <description>Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours</description>
    <arm_group_label>Rotigotine in Japanese subjects</arm_group_label>
    <arm_group_label>Rotigotine in Caucasian subjects</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is healthy according to assessments done at eligibility assessment (medical
             history, physical examination, blood pressure, heart rate, ECG, hematology, clinical
             chemistry, urinalysis)

          -  Subject is of normal body-weight as determined by a body mass index ranging between 18
             to 28 kg/m²

          -  Subject is Japanese or Caucasian. Japanese subjects are born in Japan and left Japan
             not more than 10 years ago. Both parents of the Japanese subjects are 100 % Japanese

        Exclusion Criteria:

          -  Subjects (females) without medically adequate contraception or on lactation or
             pregnant women. Subjects with oral contraception or hormone replacement within 4 weeks
             prior to eligibility assessment

          -  Subject has a history of chronic alcohol or drug abuse

          -  Subject has a consumption of more than 20 g of alcohol/day (amount corresponds to 0.5
             l of beer/day or 0.25 l of wine/day or 3 glasses (à 2 cl) of liquor/day)

          -  Subject has a clinically relevant allergy

          -  Subject has a known or suspected drug hypersensitivity in particular, to any component
             of the trial medication

          -  Subject has any clinically significant abnormality in physical examination

          -  Subject has a heart rate at rest less than 50 beats per minute (bpm) or more than 100
             bpm

          -  Subject has systolic blood pressure lower than 100 mmHg or higher than 145 mmHg or
             diastolic blood pressure higher than 95 mmHg or lower than 60 mmHg

          -  Subject has an atopic or eczematous dermatitis and/or an active skin disease or skin
             tumors

          -  Subject has a history of significant skin hypersensitivity to adhesives or other
             transdermal products or recent unresolved contact dermatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>Neupro</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <keyword>Male</keyword>
  <keyword>Female</keyword>
  <keyword>Single dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

